Nplate is a prescription medication used to increase platelet count in the blood. The drug can cause side effects such as dizziness, joint and muscle pain, blood clots, and allergic reactions. A ...

Nplate (romiplostim) is a prescription drug that works to treat thrombocytopenia by activating bone marrow cells to make more platelets. Your response to this drug may vary based on your medical ...

Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "Nplate (Romiplostim) Romiplate - Drug Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. Nplate (romiplostim ...

In Nplate® (romiplostim) clinical trials of patients with myelodysplastic syndromes (MDS) and severe thrombocytopenia, progression from MDS to acute myelogenous leukemia (AML) has been observed.

Amgen’s Nplate (romiplostim) has demonstrated efficacy in treating thrombocytopaenia among gastrointestinal (GI) cancer patients, as Phase III RECITE results are presented at ASCO 2025. In the Phase ...

THOUSAND OAKS, Calif., Dec. 13, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that data from several key Nplate ® (romiplostim) studies were presented at the 53rd Annual Meeting and ...

As with other drugs, Nplate (romiplostim) can cause side effects such as dizziness and insomnia. If you are not able to tolerate the side effects of Nplate, talk with your doctor or pharmacist. Nplate ...

Nplate (romiplostim) is a subcutaneous injection given by a healthcare professional. Your dose depends on your body weight. For ITP, Nplate is given once per week. For radiation sickness, it’s given ...

Nplate may be considered as a second-line treatment for adult non-splenectomized ITP patients for whom surgery is contraindicated. Important U.S. Nplate Safety Information Serious adverse reactions ...

Amgen Inc. has announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nplate™ (romiplostim), the first and only platelet producer for the treatment of thrombocytopenia ...

THOUSAND OAKS, Calif., Dec. 6, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has modified the requirements of the Nplate® (romiplostim) Risk ...